Prestige BioPharma said Tuesday that it has hired Dr. Julien Rea from AbbVie as the director of Global Commercial Operations to lead the global commercialization of its Herceptin biosimilar Tuznue (trastuzumab).
The newly appointed commercial director, Dr. Julien Rea, poses at the Prestige BioPharma booth at ESMO ASIA2024 in Singapore. (Courtesy of Prestige BioPharma)
The newly appointed commercial director, Dr. Julien Rea, poses at the Prestige BioPharma booth at ESMO ASIA2024 in Singapore. (Courtesy of Prestige BioPharma)
Director Rea, who holds a master's degree in marketing from EM Lyon Business School and a Ph.D. in Pharmacy from the University of Lyon, has extensive experience in global pharmaceutical companies, including Servier, Abbott, and AbbVie, where he led the sales strategy for the Humira portfolio, exceeding revenue targets for five consecutive years. He is recognized for his financial excellence in profit-loss management, business valuation, and supply management.
In anticipation of Tuznue’s European advance, Prestige BioPharma has made several organizational changes, including recruiting Director Rea and appointing a supply chain expert from Beringer Ingelheim.
Based on more than 20 years of global marketing and sales experience, Rea will lead the commercialization strategy for the company's biosimilar pipeline and antibody drugs, including Tuznue.
Rea recently made his first official appearance at ESMO ASIA 2024 in Singapore. During the congress, Prestige BioPharma's booth received visits from healthcare professionals worldwide, and Director Rea actively promoted the company's flagship anticancer products.
“We are focusing on our commercialization strategy based on the European approval of Tuznue,” a Prestige BioPharma official said. “We will accelerate developing new markets for new biosimilars based on Director Rea's expertise.”
Related articles
Prestige BioPharma opens Korea’s largest innovative drug R&D center in Busan
Prestige BioPharma secures EC approval for Herceptin biosimilar Tuznue
Prestige BioPharma targets $22.4 bil. market cap by 2030 with biosimilars, cancer treatments
Prestige BioPharma secures EMA's positive opinion for Herceptin biosimilar
Kim Chan-hyuk kch@docdocdoc.co.kr
[See Other Articles](/news/articleList.html?sc_area=I&sc_word=Kim Chan-hyuk&view_type=sm)
Copyright © KBR Unauthorized reproduction, redistribution prohibited
SNS 기사보내기
Tagrisso (osimertinib), a targeted therapy, has received approval for treating patients with unresectable stage 3 EGFR-mutated (Ex19del, L858R substitution) non-small cell lung cancer (NSCLC) whose disease has not progressed during or after platinum-based chemotherapy and radiation therapy for which there are no targeted therapy options.
AstraZeneca’s lung cancer treatment Tagrisso (Courtesy of AstraZeneca Korea)
AstraZeneca’s lung cancer treatment Tagrisso (Courtesy of AstraZeneca Korea)
AstraZeneca Korea said it received an expanded indication from the Ministry of Food and Drug Safety (MFDS) for Tagrisso to treat EGFR-mutant NSCLC last Friday.
That allows Tagrisso monotherapy to be used for treating patients with unresectable locally advanced NSCLC who have an EGFR exon 19 deletion or exon 21 (L858R) substitution and whose disease has not progressed during or after platinum-based chemotherapy and radiotherapy.
In addition, Targriso is approved in Korea for the first-line treatment of patients with locally advanced or metastatic NSCLC with an EGFR exon 19 deletion or exon 21 substitution.
ㆍ For combination with pemetrexed and platinum-based chemotherapy in the first-line treatment of patients with locally advanced or metastatic non-squamous NSCLC with an EGFR exon 19 deletion or exon 21 substitutions.
ㆍ For combination with pemetrexed and platinum-based chemotherapy in the first-line treatment of patients with locally advanced or metastatic non-squamous NSCLC with an EGFR exon 19 deletion or exon 21 substitution.
ㆍ For treating patients previously treated with an EGFR- TKI in treating patients with EGFR T790M mutation-positive locally advanced or metastatic NSCLC who have been previously treated with an EGFR- TKI.
ㆍ For adjuvant treatment after complete tumor resection in patients with EGFR exon 19 deletion or exon 21 substitution mutated NSCLC, it is the broadest indication for a targeted therapy in EGFR-mutated NSCLC.
The study (LAURA) that supported this indication expansion was a randomized, double-blind, placebo-controlled, multicenter, global phase 3 trial in patients with unresectable stage 3 EGFR-mutant NSCLC whose disease had not progressed after platinum-based chemotherapy and radiation therapy.
Results showed that Tagrisso reduced the risk of disease progression or death by 84 percent compared to placebo. Median progression-free survival (mPFS) in the Tagrisso arm was 39.1 months, 33.5 months longer than placebo (5.6 months). In addition, safety and tolerability were similar to the safety profile of each prior treatment, with no new safety concerns identified.
“The LAURA trial demonstrated a progression-free survival of 39.1 months in the Tagrisso arm, confirming a survival benefit of more than three years,” said Professor Kim Hye-ryun of the Department of Medical Oncology at Severance Hospital. “With this approval, patients with unresectable stage 3 EGFR-mutant NSCLC who have not had a targeted therapy option before can benefit from Tagrisso. The drug sets a new standard for treating unresectable stage 3 EGFR-mutant NSCLC.”
Lim Jae-yun, executive vice president for medical affairs at AstraZeneca Korea, said, “This indication expansion allows patients with all stages of EGFR-mutant NSCLC to benefit from Targriso. It will further solidify Tagrisso's value as a backbone treatment for EGFR-mutant NSCLC. We will continue to build on Tagrisso's innovative therapeutic value to improve survival and quality of life for patients with EGFR-mutant NSCLC.”
tweet
Related articles
Lung cancer experts call for fairer execution of health insurance finance
‘Tagrisso reduces early lung cancer patients’ recurrence risk by 80%’
AstraZeneca's Tagrisso reaffirms its global standing in lung cancer treatment
Korea's homegrown Leclaza gains momentum in NSCLC treatment, awaits global expansion
Tepmetko offers potential follow-up cure for Tagrisso-resistant lung cancer patients
Kim Kyoung-Won kkw97@docdocdoc.co.kr
See Other Articles
Copyright © KBR Unauthorized reproduction, redistribution prohibited